Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Recommendation of “Moderate Buy” from Analysts

Cogent Biosciences, Inc. (NASDAQ:COGT) has earned a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have issued a buy rating and three have given a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $39.5455.

A number of analysts have issued reports on the company. Leerink Partners raised their target price on Cogent Biosciences from $18.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, November 10th. Stifel Nicolaus upgraded shares of Cogent Biosciences from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research report on Monday, November 10th. UBS Group raised shares of Cogent Biosciences to a “strong-buy” rating in a research note on Wednesday, January 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cogent Biosciences in a research note on Monday, December 29th. Finally, HC Wainwright raised their price target on shares of Cogent Biosciences to $52.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th.

Insiders Place Their Bets

In other news, insider Jessica Sachs sold 82,642 shares of the company’s stock in a transaction on Friday, December 26th. The stock was sold at an average price of $38.70, for a total value of $3,198,245.40. Following the transaction, the insider owned 133,938 shares of the company’s stock, valued at $5,183,400.60. This represents a 38.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John Edward Robinson sold 90,000 shares of the firm’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $38.74, for a total value of $3,486,600.00. Following the sale, the insider directly owned 140,002 shares of the company’s stock, valued at $5,423,677.48. The trade was a 39.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,737,642 shares of company stock worth $136,600,345 in the last three months. 7.29% of the stock is owned by insiders.

Institutional Investors Weigh In On Cogent Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in COGT. CWM LLC boosted its position in shares of Cogent Biosciences by 4.9% during the 4th quarter. CWM LLC now owns 5,858 shares of the technology company’s stock worth $208,000 after purchasing an additional 276 shares during the period. Steward Partners Investment Advisory LLC raised its position in Cogent Biosciences by 16.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,159 shares of the technology company’s stock valued at $77,000 after purchasing an additional 300 shares during the period. Optimize Financial Inc lifted its stake in Cogent Biosciences by 1.4% during the fourth quarter. Optimize Financial Inc now owns 33,024 shares of the technology company’s stock worth $1,173,000 after purchasing an additional 472 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Cogent Biosciences by 35.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the technology company’s stock worth $66,000 after buying an additional 488 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Cogent Biosciences by 2.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 25,014 shares of the technology company’s stock worth $888,000 after buying an additional 527 shares during the period.

Cogent Biosciences Trading Up 3.0%

Shares of Cogent Biosciences stock opened at $37.62 on Wednesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.38 and a quick ratio of 6.38. The stock’s 50 day simple moving average is $37.77 and its 200-day simple moving average is $25.76. The stock has a market cap of $5.36 billion, a P/E ratio of -22.94 and a beta of 0.45. Cogent Biosciences has a 1-year low of $3.72 and a 1-year high of $43.73.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings data on Tuesday, February 24th. The technology company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.22). Analysts predict that Cogent Biosciences will post -2.42 EPS for the current fiscal year.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.